Negative / Null Result ReportOpen accessMedicine· cited by 19

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR

Caterina Peraldo‐Neia; Giuliana Cavalloni; Elisabetta Fenocchio; Celeste Cagnazzo; Loretta Gammaitoni; Stefano Cereda; Guglielmo Nasti; Maria Antonietta Satolli · 2018 · PLoS ONE

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

The finding, in one line

“The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients.”

Abstract

The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients. Multiple mechanisms might be involved in the resistance to anti-EGFR. Here, we explored the mutation profile of EGFR extracellular domain (ECD), of tyrosine kinase domain (TKD), and its amplification status. EGFR mutational status of exons 12, 18-21 was analyzed in 57 tumors by Sanger sequencing. EGFR amplification was evaluated in 37 tumors by Fluorescent In Situ Hybridization (FISH). Kaplan-Meier curves were calculated using the log-rank test. S

Abstract by Caterina Peraldo‐Neia; Giuliana Cavalloni; Elisabetta Fenocchio; Celeste Cagnazzo; Loretta Gammaitoni; Stefano Cereda; Guglielmo Nasti; Maria Antonietta Satolli, PLoS ONE (2018) — licensed CC BY 4.0.

Read the full paper (open access)